Biogen Inc. (BIIB) News Headlines

▮ More

Date

Headline

12/13/2019 7:54:03 AM Biogen Stops Development Of Gosuranemab For Progressive Supranuclear Palsy

12/13/2019 7:40:26 AM Biogen: Primary Endpoint Of Phase 2 PASSPORT Study Was Not Met

12/3/2019 8:40:57 AM Biogen Announces Positive Phase 2 Study Results For Cutaneous Lupus Erythematosus And Systemic Lupus Erythematosus

11/22/2019 7:43:58 AM Biogen's Data Shows Improved Gastrointestinal Tolerability With Vumerity

11/22/2019 7:33:39 AM Biogen Announces Detailed Results From Phase 3 EVOLVE-MS-2 Study

11/12/2019 7:02:09 AM Alkermes Receives $150 Mln Milestone Payment From Biogen Triggered By Recent FDA Approval Of VUMERITY

11/6/2019 7:43:50 AM Biogen Enter New Deal With Samsung Bioepis To Expand Biosimilars Portfolio

10/30/2019 7:31:19 AM Biogen And Alkermes Announce FDA Approval Of VUMERITY For Multiple Sclerosis

10/23/2019 12:37:15 PM Biogen CEO Confident Its Alzheimer's Drug Will Get FDA Approval

10/22/2019 7:33:13 AM Biogen Q3 Profit Tops Estimates; Revenue Up 5% - Quick Facts

10/22/2019 7:06:20 AM Biogen Q3 EPS $8.39; Non-GAAP EPS $9.17

10/22/2019 6:52:00 AM Biogen Plans To Submit BLA For Aducanumab In Alzheimer's Disease; Shares Jump

10/22/2019 6:37:26 AM Biogen Plans To Submit BLA For Aducanumab In Early 2020

10/22/2019 6:36:02 AM Biogen Plans To Pursue Regulatory Approval For Aducanumab

10/3/2019 8:41:05 AM Biogen Canada Reports Positive Results On Spinal Muscular Atrophy Study

10/3/2019 8:01:34 AM Biogen Canada Announce Positive Results From The NURTURE Study

10/1/2019 8:26:58 AM Biogen Appoints Alfred Sandrock As EVP, Research And Development

10/1/2019 8:14:12 AM Biogen: Michael Ehlers, EVP, Research And Development, To Leave

9/13/2019 8:15:27 AM Eisai, Biogen To Discontinue Elenbecestat Phase III Studies - Quick Facts

9/13/2019 8:02:31 AM Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease